A randomised controlled trial of effectiveness and safety of Niclosamide as add on therapy to the standard of care measures in COVID-19 management
Ahmed S Abdulamir, Faiq I Gorial, Sattar Jabar Saadi, Mohammed Fauzi Maulood, Hashim Ali Hashim, Ahmed Sameer Alnuaimi, Manal K Abdulrrazaq
Annals of Medicine & Surgery, doi:10.1016/j.amsu.2021.102779
Background: COVID-19 pandemic has ignited the urge for repurposing old drugs as candidate antiviral medicines to treat novel challenges of viral infections. Niclosamide (NCS) is an anti-parasitic drug of known antiviral potential. Therefore, this study attempts to investigate the antiviral effect and safety of NCS on SARS-CoV-2 caused COVID-19 patients. Methods: Randomized controlled open label clinical trial encompassed 75 COVID-19 patients treated with standard of care plus NCS were included as experimental group and 75 COVID-19 patients treated with only standard of care therapy as control group. Survival rate, time to recovery, and side effects were the main endpoints for the assessment of the therapeutic effect and safety of NCS. Results: No significant difference between the two study groups in the incidence of death Vs recovery within 30 days of follow up(p = 1).Median survival time to cure in the NCS addon group was significantly less than controls (5 Vs 7days, Log rank p = 0.005).All the recoveries took place within 20 days in the NCS add on group, which is 10 days shorter than that in the controls (30 days), NCS add on treatment increased the risk of cure by 60% per day compared to control group (adjusted HR = 1.6,p = 0,007) after adjusting for the count of comorbidities. Additionally, two or more comorbidities reduced the risk of cure to 33% (p < 0.001).Male gender increased the risk of cure by 42% (p = 0.046). Older age group decreased the risk of recovery per day to 0.58 and 0.53 for 50-59 and 60+ years of age. Hyypertension (HT) and diabetes mellitus (DM) significantly reduced the risk of being cured per day to 0.56 (p = 0.003)and 0.65 (p = 0.039) respectively. No significant signals of safety in NCS add on therapy compared to control group. Conclusion: adding NCS to the standards of care measures increased the risk of the cure and had shorter time to stay in the hospital compared with controls., male gender increased the risk of cure, while older patients>40 years, HT, and DM decreased the risk of cure. Also, NCS add on therapy was relatively safe; hence, NCS is of clinical benefit for freeing hospital beds for more patients in pandemic crisis.
Author contribution All authors(contributed in concept or design of the study. NS, not significant.
Consent All patients signed written informed consent for participation in the study.
Registration of research Research registry UIN: researchregistry7040. At the website: www.re searchregistry.com/browse-the-registry#home/?view_2_search = researchregistry7040. &view_2_page = 1.
Guarantor Faiq I. Gorial.
Provenance and peer review Not commissioned, externally peer-reviewed.
Declaration of competing interest None.
References
Andrews, Thyssen, Lorke, The biology and toxicology of molluscicides, Bayluscide, Pharmacol Ther
Cabrita, Benedetto, Schreiber, Kunzelmann, Niclosamide repurposed for the treatment of inflammatory airway disease, JCI Insight,
doi:10.1172/jci.insight.128414Gassen, Niemeyer, Muth, SKP2 attenuates autophagy through Beclin1-ubiquitination and its inhibition reduces MERS-Coronavirus infection, Nat. Commun,
doi:10.1038/s41467-019-13659-4Gautret, Lagier, Parola, Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial, Int. J. Antimicrob. Agents,
doi:10.1016/j.ijantimicag.2020.105949Jurgeit, Mcdowell, Moese, Meldrum, Schwendener et al., Niclosamide is a proton carrier and targets acidic endosomes with broad antiviral effects, PLoS Pathog,
doi:10.1371/journal.ppat.1002976Jurgeit, Mcdowell, Moese, Meldrum, Schwendener et al., Niclosamide is a proton carrier and targets acidic endosomes with broad antiviral effects, PLoS Pathog,
doi:10.1371/journal.ppat.1002976Jurgeit, Moese, Roulin, An RNA replication-center assay for high content image-based quantifications of human rhinovirus and coxsackievirus infections, Virol. J,
doi:10.1186/1743-422X-7-264Ko, Chang, Byun, Screening of FDA-approved drugs using a MERS-CoV clinical isolate from South Korea identifies potential therapeutic options for COVID-19, Viruses,
doi:10.3390/v13040651Laujwy, Rosin, Agha, The CONSORT (CONsolidated standards of reporting trials) 2010 guideline, Int. J. Surg
Lin, Lu, Cao, Li, Hypothesis for potential pathogenesis of SARS-CoV-2 infection-a review of immune changes in patients with viral pneumonia, Emerg. Microb. Infect,
doi:10.1080/22221751.2020.1746199Lou, Sun, Rao, Current progress in antiviral strategies, Trends Pharmacol. Sci
Miner, Labitzke, Liu, Drug repurposing: the anthelmintics niclosamide and nitazoxanide are potent TMEM16A antagonists that fully bronchodilate airways, Front. Pharmacol,
doi:10.3389/fphar.2019.00051Multicenter, Adaptive, Randomized Blinded Controlled Trial of the Safety and Efficacy of Investigational Therapeutics for the Treatment of COVID-19 in Hospitalized Adults, ClinicalTrials
Pan, Ding, Wang, Niclosamide, an old antihelminthic agent, demonstrates antitumor activity by blocking multiple signaling pathways of cancer stem cells, Chin. J. Canc,
doi:10.5732/cjc.011.10290Pindiprolu, Pindiprolu, CD133 receptor mediated delivery of STAT3 inhibitor for simultaneous elimination of cancer cells and cancer stem cells in oral squamous cell carcinoma, Med. Hypotheses,
doi:10.1016/j.mehy.2019.109241Rajamuthiah, Fuchs, Conery, Repurposing salicylanilide anthelmintic drugs to combat drug resistant Staphylococcus aureus, PloS One,
doi:10.1371/journal.pone.0124595Yu, Du, Ojcius, Pan, Jiang, Measures for diagnosing and treating infections by a novel coronavirus responsible for a pneumonia outbreak originating in Wuhan, China, Microb. Infect,
doi:10.1016/j.micinf.2020.01.003Zhang, Liu, Potential interventions for novel coronavirus in China: a systematic review, J. Med. Virol,
doi:10.1002/jmv.25707{ 'indexed': { 'date-parts': [[2023, 11, 17]],
'date-time': '2023-11-17T06:42:51Z',
'timestamp': 1700203371774},
'reference-count': 0,
'publisher': 'Ovid Technologies (Wolters Kluwer Health)',
'license': [ { 'start': { 'date-parts': [[2021, 9, 1]],
'date-time': '2021-09-01T00:00:00Z',
'timestamp': 1630454400000},
'content-version': 'tdm',
'delay-in-days': 0,
'URL': 'https://www.elsevier.com/tdm/userlicense/1.0/'},
{ 'start': { 'date-parts': [[2021, 9, 2]],
'date-time': '2021-09-02T00:00:00Z',
'timestamp': 1630540800000},
'content-version': 'vor',
'delay-in-days': 1,
'URL': 'http://creativecommons.org/licenses/by-nc-nd/4.0/'}],
'content-domain': { 'domain': [ 'clinicalkey.fr', 'clinicalkey.jp', 'clinicalkey.es', 'clinicalkey.com.au',
'clinicalkey.com', 'elsevier.com', 'sciencedirect.com'],
'crossmark-restriction': True},
'published-print': {'date-parts': [[2021, 9]]},
'DOI': '10.1016/j.amsu.2021.102779',
'type': 'journal-article',
'created': {'date-parts': [[2021, 9, 4]], 'date-time': '2021-09-04T06:01:57Z', 'timestamp': 1630735317000},
'update-policy': 'http://dx.doi.org/10.1016/elsevier_cm_policy',
'source': 'Crossref',
'is-referenced-by-count': 15,
'title': 'A randomised controlled trial of effectiveness and safety of Niclosamide as add on therapy to '
'the standard of care measures in COVID-19 management',
'prefix': '10.1097',
'volume': '69',
'author': [ {'given': 'Ahmed S.', 'family': 'Abdulamir', 'sequence': 'first', 'affiliation': []},
{'given': 'Faiq I.', 'family': 'Gorial', 'sequence': 'additional', 'affiliation': []},
{'given': 'Sattar Jabar', 'family': 'Saadi', 'sequence': 'additional', 'affiliation': []},
{'given': 'Mohammed Fauzi', 'family': 'Maulood', 'sequence': 'additional', 'affiliation': []},
{'given': 'Hashim Ali', 'family': 'Hashim', 'sequence': 'additional', 'affiliation': []},
{'given': 'Ahmed Sameer', 'family': 'Alnuaimi', 'sequence': 'additional', 'affiliation': []},
{'given': 'Manal K.', 'family': 'abdulrrazaq', 'sequence': 'additional', 'affiliation': []}],
'member': '276',
'container-title': 'Annals of Medicine & Surgery',
'original-title': [],
'language': 'en',
'link': [ { 'URL': 'https://api.elsevier.com/content/article/PII:S2049080121007299?httpAccept=text/xml',
'content-type': 'text/xml',
'content-version': 'vor',
'intended-application': 'text-mining'},
{ 'URL': 'https://api.elsevier.com/content/article/PII:S2049080121007299?httpAccept=text/plain',
'content-type': 'text/plain',
'content-version': 'vor',
'intended-application': 'text-mining'},
{ 'URL': 'https://journals.lww.com/10.1016/j.amsu.2021.102779',
'content-type': 'unspecified',
'content-version': 'vor',
'intended-application': 'similarity-checking'}],
'deposited': { 'date-parts': [[2023, 3, 12]],
'date-time': '2023-03-12T23:06:36Z',
'timestamp': 1678662396000},
'score': 1,
'resource': {'primary': {'URL': 'https://journals.lww.com/10.1016/j.amsu.2021.102779'}},
'subtitle': [],
'short-title': [],
'issued': {'date-parts': [[2021, 9]]},
'references-count': 0,
'URL': 'http://dx.doi.org/10.1016/j.amsu.2021.102779',
'relation': {},
'ISSN': ['2049-0801'],
'subject': ['General Medicine', 'Surgery'],
'published': {'date-parts': [[2021, 9]]},
'assertion': [ {'value': 'Elsevier', 'name': 'publisher', 'label': 'This article is maintained by'},
{ 'value': 'A randomised controlled trial of effectiveness and safety of Niclosamide as add '
'on therapy to the standard of care measures in COVID-19 management',
'name': 'articletitle',
'label': 'Article Title'},
{ 'value': 'Annals of Medicine and Surgery',
'name': 'journaltitle',
'label': 'Journal Title'},
{ 'value': 'https://doi.org/10.1016/j.amsu.2021.102779',
'name': 'articlelink',
'label': 'CrossRef DOI link to publisher maintained version'},
{'value': 'article', 'name': 'content_type', 'label': 'Content Type'},
{ 'value': '© 2021 The Authors. Published by Elsevier Ltd on behalf of IJS Publishing Group '
'Ltd.',
'name': 'copyright',
'label': 'Copyright'}]}
